Navigation Links
Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
Date:4/9/2009

SUNNYVALE, Calif., April 9 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its fiscal first quarter ended March 31, 2009, on Thursday, April 23, 2009, after the close of the market.

The company will host a management presentation at 2 p.m. Pacific Time on Thursday, April 23, 2009, to discuss the results. To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

Interested participants and investors may also listen to the live teleconference call by dialing (866) 700-6067 (domestic) or (617) 213-8834 (international), and entering participant code 21782083. A replay will be available for seven days beginning at 4 p.m. Pacific Time. Access numbers for this replay are (888) 286-8010 (domestic) and (617) 801-6888 (international), with participant code 78028998.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection
'/>"/>

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
2. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
5. Cepheid Reports Third Quarter Revenue of $44.9 Million
6. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
7. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
8. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
9. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
10. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  U.S. biotech company Kultevat ... license for technology developed by the Donald Danforth ... plants, including for applications in production of natural rubber ... technology was developed under the direction of Roger ... former president of the Danforth Plant Science Center, and ...
(Date:9/18/2014)... 2014 Mapi, société créée à ... été depuis 40 ans l,un des pionniers ... par des évaluations recentrées sur le patient ... économiques des traitements. Logo - ... cours d,une récente conférence téléphonique avec l,ensemble ...
(Date:9/18/2014)... rare diseases that afflict skeletal growth through abnormalities ... the fetal stage and is caused by genetic ... growth factor receptor 3 (FGFR3) has been associated ... (TD), a skeletal dysplasia that cause serious respiratory ... achondroplasia (ACH), which causes stunted growth and other ...
(Date:9/18/2014)... everything we touch in the course of a ... even medicines, rely on the chemical industry to ... and farm products into valuable chemicals that are ... scientist Dr Sarina Sarina, who achieved outstanding progress ... at ambient temperature using light instead of fossil ...
Breaking Biology Technology:Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Using solar energy to turn raw materials into ingredients for every day life 2
... 7 Amsterdam Molecular,Therapeutics (Euronext: AMT), a leader ... the treatment of the first patient in a ... targets,lipoprotein lipase deficiency (LPLD), a seriously debilitating and,potentially ... randomized controlled trial has been designed to gather ...
... Kendle (Nasdaq: KNDL ), a leading, global ... or $0.06 per share for the first quarter 2009 compared ... share for the first quarter 2008. On a pro forma ... $0.47 per diluted share compared with $0.38 per diluted share ...
... Amgen (Nasdaq: AMGN ), today announced ... Stockholders, held at The St. Regis Hotel, San Francisco, ... represented at the meeting.The director nominees: David Baltimore, Frank ... Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, ...
Cached Biology Technology:AMT Starts Preregistration Trial for Glybera(TM) 2AMT Starts Preregistration Trial for Glybera(TM) 3Kendle Announces First Quarter 2009 Results 2Kendle Announces First Quarter 2009 Results 3Kendle Announces First Quarter 2009 Results 4Kendle Announces First Quarter 2009 Results 5Kendle Announces First Quarter 2009 Results 6Kendle Announces First Quarter 2009 Results 7Kendle Announces First Quarter 2009 Results 8Amgen Announces Voting Results Of Annual Meeting Of Stockholders 2
(Date:9/19/2014)... A new study shows that legume plants regulate ... cytokininssignaling molecules that are transmitted through the plant ... the number of bacteria-holding nodules in the roots. ... the National Institute for Basic Biology, the Graduate ... Center for Sustainable Resource Science in Japan. ...
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive brainstem ... by researchers at Harvard School of Medicine and the ... this is only the second "sleep node" identified in ... necessary and sufficient to produce deep sleep. , Published ... study demonstrates that fully half of all of the ...
(Date:9/18/2014)... robotic system that can operate inside the bore of ... of a biomedical research partnership program at Brigham and ... if the robot, in conjunction with real-time MRI images, ... costly, and less discomforting for the patient. The novel ... therapies with greater precision. , Developed by a team ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... harnessing of 'T-rays' - electromagnetic terahertz waves - which ... varied as biological cell abnormalities and explosives has been announced. ... in Spain have said they have found a way to ... Their findings are set out in a letter published in ...
... heart is removed, the dynamic interplay between a mass ... the protective cell layer that covers the wound spurs ... Medical Center scientists have found. , The scientists further ... the cell mass and the protective covering, encouraging the ...
... Institute of Virology and Immunology (GIVI) have identified a previously ... HIV, a finding that may lead to new approaches for ... Oct. 2, 2006, in Proceedings of the National Academy of ... laboratory of GIVI Director Warner C. Greene, MD, PhD, explains ...
Cached Biology News:T-ray breakthrough could make detecting disease far easier 2Key to zebrafish heart regeneration uncovered 2Key to zebrafish heart regeneration uncovered 3Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
...
Mouse monoclonal [CAT-2] to Chloramphenicol Acetyltransferase...
Recommended fro Western blotting application...
Biology Products: